The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Regulation of osteoclastic activity is critical for understanding bone loss associated with the postmenopausal period. In vitro and animal studies have revealed the role of OPG as a decoy receptor that neutralizes the effect of RANKL on the differentiation and activation of osteoclasts. However, the role of the OPG-RANKL system in postmenopausal osteoporosis is controversial. Thus, the aim of this study was to investigate the relationship among circulating levels of OPG, RANKL, bone turnover markers (BTM), bone mineral density (BMD) and vertebral fractures in postmenopausal women. We determined anthropometric parameters, circulating OPG and RANKL, BTM, estradiol, BMD by dual X-ray absorptiometry at the lumbar spine (LS) and femoral neck (FN), and pre-existing vertebral fractures in 206 ambulatory postmenopausal women of a mean age of 62 years (SD 7). Circulating OPG was significantly related to age (r =0.158; P =0.023), years since menopause (r =0.167; P =0.016) and BMD (LS Z-score: r =0.240; P =0.001, FN Z-score: r =0.156; P =0.025). Over half of the women had undetectable RANKL (n =113; 54.9%). There were no significant differences in clinical variables, BTM or BMD among women with detectable vs. undetectable RANKL. OPG was found to be independently associated with osteoporosis (OR: 2.9, 1.4-5.9) and prevalent vertebral fractures (OR: 2.5, 1.2-5.4). We conclude that serum OPG levels are independently associated with bone mass and prevalent vertebral fractures in postmenopausal women.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the evidence is conflicting about an association between markers of bone turnover and circulating OPG because some studies report an association (154,372,375) or an association only among osteoporotic women (384), and others report no association (373,379).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [379]
In the citing paper
“However, in one of the studies over half of the women (54.9%) had concentrations of RANKL that were undetectable (379), and in the other study 40% of samples were below the detection limit of the assay (385).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [379]
In the citing paper
“Residual estrogen levels after the menopause correlate with bone density and fracture risk, yet the relationship of estrogen levels with serum OPG levels in postmenopausal women has been inconsistent across studies, with some supporting a weak relationship (375) and others no relationship (373, 379) or a negative correlation (381).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [379]
In the citing paper
“Serum RANKL levels have also been investigated in postmenopausal women and reported not to be associated with menopausal status or BMD (379, 385) but to be associated with nontraumatic fracture (385).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [379]
In the citing paper
“Serum OPG levels have been found to be positively related to BMD (375, 379), negatively related to BMD (374, 383), or unrelated to BMD (372, 373) in postmenopausal women.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [379]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · cited 1×
“Moreover, OPG administration protects against the decrease in bone mass that occurs in the ovariectomized/estrogen-deficient rat model of postmenopausal osteoporosis [8].”
Background(1994) · PubMed · Cited by 5,043
ASSESSMENT OF FRACTURE RISK AND ITS APPLICATION TO SCREENING FOR POSTMENOPAUSAL OSTEOPOROSIS
Alexeeva, L. P., Burkhardt, P., Christiansen, C., Cooper, C. C., Delmas, P. D., Johnell, O., Johnston, C. C., Kanis, J. A., Lips, P. T. A. M., Melton, L. J., et al. (1994) · Cited by 2,655
Sex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846 · cited 1×
“It appears likely that estrogens inhibit bone resorption by inducing small but cumulative changes in multiple estrogen-dependent regulatory factors [28].”
BackgroundYasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201 · cited 1×
“In prior in vitro and animal studies, OPG has been shown to reduce or prevent increased bone resorption [2, 3].”
BackgroundHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,173 · cited 2×
“In addition, OPG and RANKL have been implicated in the pathogenesis of osteoporosis and other metabolic bone diseases [1].”
BackgroundRole of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 3×
“[9], which is likely to be the result of the actions of other cytokines.”
BackgroundInfluentialBekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771 · cited 2×
“In prior in vitro and animal studies, OPG has been shown to reduce or prevent increased bone resorption [2, 3]. Both OPG [4] and RANKL antibody [ 5 ] administration to humans have been demonstrated to cause marked decreases in bone resorption.”
BackgroundHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 3×
“Recent pharmacological studies have shown that estrogen increases osteoblast production of OPG [6] and inhibits RANKLmediated osteoclastogenesis [7] in in-vitro and rodent models.”
BackgroundBrowner, W. S., Lui, L.-Y., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7192 · Cited by 506 · cited 2×
“[12] observed a significant negative correlation between OC and OPG.”
Background
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Dimorphic effects of Notch signaling in bone homeostasis
Engin, F., Yao, Z., Yang, T., Zhou, G., Bertin, T., Jiang, M. M., Chen, Y., Wang, L., Zheng, H., Sutton, R. E., et al. (2008) · Nature Medicine · doi:10.1038/nm1712 · Cited by 413
“Moreover, it raises the question of whether loss of Notch signaling contributes to age-related osteoporosis, as this type of osteoporosis is associated with increased resorption over bone formatio”
BackgroundTanaka, S., Nakamura, K., Takahasi, N., & Suda, T. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00327.x · Cited by 320
Goëb, V., & Anne-Priscille, T. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s10153 · Cited by 179
“In several other cohorts, no correlation was found between OPG and bone resorption markers in women whatever their menopause status was.(36,40) In contrast, a positive relationship between bone turnover markers and OPG was found in postmenopausal women(41) and in both men and women in a study by Indridason et al.”
The link between osteoporosis and cardiovascular disease.
Farhat, G. N., & Cauley, J. A. (2008) · PubMed Central · Cited by 194
Scott, J. P. R., Sale, C., Greeves, J. P., Casey, A., Dutton, J., & Fraser, W. D. (2011) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00764.2010 · Cited by 137
“Previous studies have shown that RANKL is undetectable in 70% of healthy controls (27) and 55% of postmenopausal women (41), making the true RANKL response to exercise impossible to determine with current assay technology.”
BackgroundPathophysiological roles of osteoprotegerin (OPG)
Reid, P., & Holen, I. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.06.004 · Cited by 144
Ndip, A., Williams, A., Jude, E. B., Serracino‐Inglott, F., Richardson, S., Smyth, J. V., Boulton, A. J. M., & Alexander, M. Y. (2011) · Diabetes · doi:10.2337/db10-1220 · Cited by 141
Lipid metabolism disorders and bone dysfunction-interrelated and mutually regulated (Review)
Tian, L., & Yu, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3472 · Cited by 143
“In postmenopausal females, OPG levels were significantly and independently positively correlated with bone mass and prevalent vertebral fractures (34).”
BackgroundOsteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis
Jabbar, S., Drury, J., Fordham, J. N., Datta, H. K., Francis, R. M., & Tuck, S. P. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.086595 · Cited by 107
Rochette, L., Méloux, A., Rigal, E., Zeller, M., Cottin, Y., & Vergely, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.015 · Cited by 112
Biver, E., Chopin, F., Coiffier, G., Funck‐Brentano, T., Bouvard, B., Garnero, P., & Cortet, B. (2011) · Joint Bone Spine · doi:10.1016/j.jbspin.2011.05.003 · Cited by 114
Scott, J. P. R., Sale, C., Greeves, J. P., Casey, A., Dutton, J., & Fraser, W. D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2516 · Cited by 100
Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver
Musso, G., Paschetta, E., Gambino, R., Cassader, M., & Molinaro, F. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.006 · Cited by 102
Immune changes in post-menopausal osteoporosis: the Immunos study
Breuil, V., Ticchioni, M., Testa, J., Roux, C. H., Ferrari, P. P., Breittmayer, J. P., Albert-Sabonnadière, C., Durant, J., Perreti, F. D., Bernard, A., et al. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1018-7 · Cited by 91
“In the literature, serum OPG and RANKL have been described to be associated with age and estradiol level, which were similar in both of our groups, with bone turnover, which was higher in our OP group, and with BMD status, which was lower in our OP group [35-37].”
ResultYilmaz, Y. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05196.x · Cited by 82
Dobnig, H., Hofbauer, L. C., Viereck, V., Obermayer-Pietsch, B., & Fahrleitner-Pammer, A. (2006) · Osteoporosis International · doi:10.1007/s00198-005-0035-4 · Cited by 76
“In various cross-sectional studies, measurements of serum OPG levels have been found to be either correlated [18, 19] or not correlated [20, 21] to bone density, whereas the local expression of OPG mRNA levels in iliac bone biopsies has been correlated with increased fracture susceptibility [22].”
BackgroundRelationship between serum RANKL and RANKL in bone
Findlay, D. M., & Atkins, G. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1740-9 · Cited by 85
“Thus, at least with some assays, many individuals have free serum RANKL levels below the limit of detection [41].”
BackgroundStern, A., Laughlin, G. A., Bergstrom, J., & Barrett-Connor, E. L. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0753 · Cited by 81
“Published findings of serum OPG-bone mineral density (BMD) associations in humans have been inconsistent (3, 11‐18), and few studies have assessed the associations of RANKL (18‐20) and the RANKL/ OPG ratio (20, 21 ) with BMD.”
BackgroundMethodResultInfluentialPino, A. M., Ríos, S., Astudillo, P., Fernández, M., Figueroa, P., Seitz, G., & Rodríguez, J. P. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090802 · Cited by 76
Li, E. K., Tam, L., Griffith, J. F., ZHU, T. Y., Li, T. K., Li, M., Wong, K. C., Chan, M. M., Lam, C. W. K., Chu, F. S. K., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081337 · Cited by 75
Ueland, T., Bollerslev, J., Wilson, S. G., Dick, I. M., Islam, A. F. M., Mullin, B. H., Devine, A., & Prince, R. L. (2006) · Bone · doi:10.1016/j.bone.2006.06.022 · Cited by 71
“However, a recent study demonstrated a weak positive association between circulating OPG and bone mass and vertebral fractures in 206 ambulatory postmenopausal Spanish women [38].”
BackgroundGenetic epidemiology of age-related osteoporosis and its clinical applications
Cheung, C., Xiao, S., & Kung, A. W. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.106 · Cited by 72
Azizieh, F. Y., Shehab, D., Al-Jarallah, K. F., Gupta, R., & Raghupathy, R. (2019) · Biomarker Insights · doi:10.1177/1177271919843825 · Cited by 79
Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
Filip, R., Radzki, R., & Bieńko, M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s170533 · Cited by 60
Voskaridou, E., Stoupa, E., Antoniadou, L., Premetis, E., Konstantopoulos, K., Papassotiriou, I., & Terpos, E. (2006) · PubMed · Cited by 63
Chen, S., Lin, C., Lin, C., & Kao, C. (2015) · Medicine · doi:10.1097/md.0000000000001146 · Cited by 82
González-Calvin, J. L., Mundi, J. L., Casado-Caballero, F. J., Abadia, A. C., & Martin-Ibañez, J. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0835 · Cited by 53
“The prevalence of osteoporosis in our control postmenopausal women is similar to that previously reported for women in this age range from the same geographic area (27) and other countries (28).”
ResultWagner, D., & Fahrleitner‐Pammer, A. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0818-x · Cited by 60
“In a cohort of postmenopausal women, more than half of the population had undetectable RANKL levels [ 25 ].”
BackgroundSamelson, E. J., Broe, K. E., Demissie, S., Beck, T., Karasik, D., Kathiresan, S., & Kiel, D. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2492 · Cited by 49
“(29), who found a positive association between OPG and femoral neck bone density in a clinical study of postmenopausal women conducted in Spain.”
BackgroundMartín-Bautista, E., Muñoz‐Torres, M., Fonollá, J., Quesada, M., Poyatos-Andújar, A., & López‐Huertas, E. (2010) · Nutrition Research · doi:10.1016/j.nutres.2010.05.007 · Cited by 52
Self-citationOsteoprotegerin Lys3Asn Polymorphism and the Risk of Fracture in Older Women
Moffett, S. P., Oakley, J. I., Cauley, J. A., Lui, L.-Y., Ensrud, K. E., Taylor, B. C., Hillier, T. A., Hochberg, M., Li, J., Cayabyab, S., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1019 · Cited by 45
Speer, G., Fekete, B. C., Othmane, T., Szabó, T., Egresits, J., Fodor, E., Kiss, I., Logan, A. G., Nemcsik, J., Szabó, Á., et al. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn242 · Cited by 44
“OPG may serve as a protective mechanism to slow down the increased bone resorption and subsequent bone loss [25].”
BackgroundRaloxifene therapy interacts with serum osteoprotegerin in postmenopausal women
Messalli, E. M., Mainini, G., Scaffa, C., Cafiero, A. C., Salzillo, P. L., Ragucci, A., & Cobellis, L. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.05.007 · Cited by 42
RANKL inhibition for the management of patients with benign metabolic bone disorders
Anastasilakis, A. D., Toulis, K. A., Pοlyzos, S. A., & Terpos, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048929 · Cited by 39
“Mean increase in hip BMD was 1.6 – 3.6% at 12 and 3.4 – 5.1% at 24 months.”
BackgroundInfluentialNabipour, I., Larijani, B. A., Vahdat, K., Assadi, M., Jafari, S. M., Ahmadi, E., Movahed, A., Moradhaseli, F., Sanjdideh, Z., Obeidi, N., et al. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181a181b8 · Cited by 41
Circulating Osteoprotegerin and Soluble RANK Ligand in Systemic Sclerosis
Dovio, A., Data, V., CARIGNOLA, R., CALZOLARI, G., Vitetta, R., Ventura, M., Saba, L., Severino, A., & Angeli, A. (2008) · The Journal of Rheumatology · doi:10.3899/jrheum.080192 · Cited by 37
“Previous studies looking at correlations between serum sRANKL levels and bone mass or bone turnover markers in healthy women have yielded conflicting results, with authors reporting negative 27,35-37 , positive 38,39 , or no association 40-42 with bone density.”
ResultOsteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes
O'Sullivan, E. P., Ashley, D. T., Davenport, C., Devlin, N. F. C., Crowley, R. K., Agha, A., Thompson, C. J., O’Gorman, D. J., & Smith, D. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1109 · Cited by 38
“In addition to the large standard deviations which we encountered, others have found levels to be undetectable in over half the samples tested [32].”
BackgroundMonegal, A., Navasa, M., Peris, P., Alvarez, L., Pons, F., Rodés, J., & Guañabens, N. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01448.x · Cited by 31
“Moreover, it should be noted that in healthy and in osteoporotic postmenopausal populations the relationship between OPG serum levels and markers of bone turnover is somewhat inconclusive, showing indistinctly positive and negative associations (15, 16).”
BackgroundJørgensen, L., Vik, A., Emaus, N., Brox, J. H., HANSEN, J. ‐., Mathiesen, E. B., & Vestergaard, P. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1035-6 · Cited by 30
“About half of all previous studies included postmenopausal women only [5, 6, 9, 13, 15, 17, 21, 28].”
BackgroundResultInfluentialPiedra, M., García‐Unzueta, M. T., Berja, A., Paule, B., Lavín, B. A., Valero, C., Riancho, J. A., & Amado, J. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-168 · Cited by 29
“OPG serum levels were three times higher in our PHPT patients than in a previous study on men and women aged 62 with PHPT [36] and our PHPT subjects had lower levels than a group of postmenopausal women [37].”
ResultOsteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status
O'Sullivan, E. P., Ashley, D. T., Davenport, C., Kelly, J. J., Devlin, N. F. C., Crowley, R. K., Leahy, A. L., Kelly, C. J., Agha, A., Thompson, C. J., et al. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.09.003 · Cited by 28
Mapping Quantitative Trait Loci for Cross-Sectional Geometry at the Femoral Neck
Shen, H., Long, J., Xiong, D.-H., Liu, Y., Liu, Y.-Z., Xiao, P., Zhao, L.-J., Dvornyk, V., Zhang, Y.-Y., Rocha-Sanchez, S. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050715 · Cited by 28
“All these samples were initially recruited for studies on BMD.(30,31) Among the 79 pedigrees, 50 pedigrees were ascertained through probands with low BMD (ZBMD −1.28 at the hip or spine, belonging to the bottom 10% in the age-matched population), 25 pedigrees were recruited through probands having high BMD (ZBMD +1.28…”
BackgroundInfluentialTGFβ inducible early gene-1 directly binds to, and represses, the OPG promoter in osteoblasts
Subramaniam, M., Hawse, J. R., Bruinsma, E. S., Grygo, S. B., Cicek, M., Oursler, M. J., & Spelsberg, T. C. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.171 · Cited by 30
“One study reported that serum OPG levels were increased in osteoporosis and another reported a correlation with bone mineral density [16-18].”
BackgroundBowsher, R. R., & Sailstad, J. M. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.09.026 · Cited by 27
Fernández‐García, D., Muñoz‐Torres, M., Mezquita‐Raya, P., de la Higuera, M., Alonso, G., Reyes‐García, R., Ochoa, A. S., Ruiz-Requena, M. E., Luna, J. D. D., & Escobar‐Jiménez, F. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346385 · Cited by 25
Self-citationOelzner, P., Franke, S., Lehmann, G., Eidner, T., Müller, A., Wolf, G., & Hein, G. E. (2007) · Clinical Rheumatology · doi:10.1007/s10067-007-0639-5 · Cited by 25
“OPG levels were found to be higher in postmenopausal women with osteoporosis and fractures in comparison to those without [49, 50 ].”
ResultTera, T. D. M., do Prado, R. F., Marco, A. C. D., Santamaria, M. P., & Jardini, M. A. N. (2014) · Brazilian Oral Research · doi:10.1590/1807-3107bor-2014.vol28.0054 · Cited by 20
Lorenzo, J. A., CANALIS, E. M., & Raisz, L. G. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00029-8 · Cited by 23
Liu, Z., Yang, Y., Wen, C.-Y., & Rong, L.-M. (2017) · BioMed Research International · doi:10.1155/2017/9892048 · Cited by 18
Amer, O. E., Wani, K., Ansari, M. G. A., Alnaami, A. M., Aljohani, N., Abdi, S., Hussain, S. D., Al‐Daghri, N. M., & Alokail, M. S. (2022) · Medicina · doi:10.3390/medicina58080976 · Cited by 19
“found that OPG and RANKL were independently correlated to vertebral fractures and osteoporosis [35].”
Osteoprotegerin as a potential therapy for osteoporosis
Hamdy, N. A. T. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-006-0026-2 · Cited by 17
“Other studies addressing the relationship between circulating concentrations of OPG and RANKL and bone mineral density (BMD) and fractures in postmenopausal women have yielded conflicting results, suggesting that it is the up-regulation of RANKL on bone marrow cells and the concentration of these molecules in the bone…”
ResultUse of Bone Turnover Markers in Osteoporosis
Lenora, J., Ivaska, K. K., & Gerdhem, P. (2009) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-009-9042-x · Cited by 20
“[105] found that OPG was independently associated with osteoporosis and prevalent vertebral fractures.”
BackgroundSerum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?
Moreno, P. R., García, R. R., García‐Martin, A., Varsavsky, M., Garcia-Salcedo, J. A., & Muñoz‐Torres, M. (2013) · PubMed · doi:10.3275/8285 · Cited by 15
Self-citationStaab, J. S., Lutz, L. J., Foulis, S. A., Gaffney‐Stomberg, E., & Hughes, J. M. (2022) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00442.2022 · Cited by 16
Reyes‐García, R., Muñoz‐Torres, M., García, D. F., Mezquita‐Raya, P., Salcedo, J. A. G., & Luna, J. D. D. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181ac0cc1 · Cited by 17
Self-citationSerum osteoprotegerin levels are related to height loss: The Tromsø Study
Jørgensen, L., Hansen, J., Brox, J. H., Mathiesen, E. B., Vik, A., & Jacobsen, B. K. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9555-8 · Cited by 15
“The cross-sectional studies have found either decreased [17] or increased [18] OPG levels in postmenopausal women with prevalent fractures.”
BackgroundTariq, S., Tariq, S., Abualhamael, S. A., & Shahzad, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.822671 · Cited by 12
“Lower circulating OPG concentrations were also independently and positively correlated with low BMD in postmenopausal females (Mezquita-Raya et al., 2005).”
BackgroundOsteoprotegerin and Bone Mass in Squamous Cell Head and Neck Cancer Patients
Valero, C., Olmos, J. M., Rivera, F., Hernández, J. L., Vega, M. E., & Macías, J. G. (2006) · Calcified Tissue International · doi:10.1007/s00223-005-0237-y · Cited by 16
Wu, X., Wu, X.-P., Luo, X., Xie, H., Zhang, H., Peng, Y., Yuan, L., Jiang, Y., & Liao, E.-Y. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.05.006 · Cited by 13
“In postmenopausal women, the circulating OPG level is a decisive factor affecting bone turnover, changes in bone mass, and the prevalence of vertebral fractures [23,24].”
BackgroundOsteoprotegerin as a potential therapy for osteoporosis
Hamdy, N. A. T. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-996-0014-5 · Cited by 16
Osteoprotegerin is associated with hip fracture incidence: the Tromso Study
Jørgensen, L., Hansen, J., Ahmed, L. A., Bjørnerem, Å., Emaus, N., Joakimsen, R. M., Mathiesen, E. B., Störmer, J., Vik, A., & Jacobsen, B. K. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys063 · Cited by 12
Boroń, D., Kotrych, D., Bartkowiak-Wieczorek, J., Uzar, I., Bogacz, A., & Kamiński, A. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.07.015 · Cited by 11
Ugay, L., Kochetkova, E., Афанасьевна, Н. В., & Maistrovskaia, Y. V. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.185857 · Cited by 16
“Dysregulation of the RANKL/RANK/OPG system can be associated with certain pathological conditions, such as postmenopausal osteoporosis, bone turnover‐associated osteolysis, and certain bone metastatic tumors, immune disease, rheumatoid arthritis, or cardiovascular pathology.[4,6,7,9,28,29] Interestingly, the data rela…”
BackgroundResultEffect of Nicotine on RANKL and OPG and Bone Mineral Density
Mızrak, S., Turan, V., İnan, S., Uysal, A., Yılmaz, C., & Ercan, G. (2014) · Journal of Investigative Surgery · doi:10.3109/08941939.2014.916369 · Cited by 11
“els and BMD scores in other studies, related to postmenopausal women [24, 25].”
ResultRelationship between serum TGF-β1, OPG levels and osteoporotic risk in native Chinese women
Xie, G., Lei, D.-D., He, H., Gong, J., Chen, C., Chen, P., Zhang, H., Luo, X., Liao, E.-Y., & Wu, X. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.04.019 · Cited by 12
Zhang, N., Wu, X., Wu, X., Fu, X., Du, X.-Y., Xie, H., Peng, Y., Luo, X., & Liao, E.-Y. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.01.021 · Cited by 10
Shilov, S. N., Teplyakov, A. T., Yakovleva, I. V., Попова, А. А., Березикова, Е. Н., Grakova, E. V., Молоков, А. В., Neupokoeva, M. N., Кобец, В. В., Kopeva, K. V., et al. (2018) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2018-7-1-6-13 · Cited by 10
Balsa, J. A., Lafuente, C., Gómez‐Martín, J. M., Galindo, J., Peromingo, R., García‐Moreno, F., Velasco, G. R., Martínez-Botas, J., Gómez‐Coronado, D., Escobar-Morreale, H. F., et al. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0712-0 · Cited by 11
“Nevertheless, the involvement of the OPG/RANKL system may be even more important in patients with osteoporosis, as already shown for idiopathic or postmenopausal osteoporosis [30–32].”
BackgroundAlbu, A., Bondor, C. I., Craciun, A. M., & Fodor, D. (2014) · Advances in Medical Sciences · doi:10.1016/j.advms.2014.08.002 · Cited by 9
Gunsser, J., Hermann, R., Roth, A. J., & Lupp, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0227133 · Cited by 8
“These findings correspond well to data from the literature showing positive associations between PTH and AP [70, 74, 75] and between OPG and AP [47].”
BackgroundResultKaradağ‐Saygı, E., Akyüz, G., Bizargity, P., & Ay, P. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2011.579657 · Cited by 11
“also showed positive correlation between circulating OPG levels with prevalent fracture [9].”
BackgroundResultInfluentialVertebral marrow fat fraction is associated with circulating RANKL in postmenopausal females
Li, X., Zuo, X., Li, L., Xu, R., Wang, Y., Chang, S., Wang, Y., Luo, P. F., & Li, G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1442046 · Cited by 8
Cucchi, D., Menon, A., Galliera, E., Messina, C., Zanini, B., Marazzi, M. G., Massaccesi, L., Compagnoni, R., Romanelli, M. M. C., & Randelli, P. S. (2018) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2018.05.039 · Cited by 8
“AC CE PT ED M AN US CR IP T levels below the limit of detection is described (20).”
BackgroundSerum Osteoprotegerin and Sex Steroid Levels in Patients With Prostate Cancer
Varsavsky, M., Reyes‐García, R., Perez, M. D., Ramírez, A. R. G., Mijan, J. L., & Muñoz‐Torres, M. (2012) · Journal of Andrology · doi:10.2164/jandrol.111.014696 · Cited by 7
Self-citationFichna, M., Żurawek, M., Fichna, P., Gryczyńska, M., Nowak, J., & Ruchała, M. (2012) · PubMed · Cited by 6
Chen, C., Liang, M.-K., Zhang, H., Peng, Y., Wu, X., Wu, X., & Liao, E.-Y. (2013) · Endocrine Research · doi:10.3109/07435800.2013.840654 · Cited by 6
“ing OPG level is a decisive factor affecting bone turnover, changes in bone mass and the prevalence of vertebral fractures (6,7).”
BackgroundLedoux, C., Boaretti, D., Sachan, A., Müller, R., & Collins, C. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.901720 · Cited by 9
Renjithlal, S. L. M., Magdi, M., Mostafa, M. R., Renjith, K., Pillai, P., Syed, M., Mohamed, S., Zahid, V. F., Ritter, N., Ali, O. A., et al. (2022) · Journal of Endocrinology and Metabolism · doi:10.14740/jem840 · Cited by 4
Osteoimmunological Insight in to Vertebral Fractures in Osteoporosis
Saghafi, H., Hossein‐Nezhad, A., Sedighi, N., Tofighi, P., Soltani, A., Larijani, B. A., & Hafezi, R. (2008) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 4
Wu, X., Peng, Y., Zhang, H., Xie, H., Sheng, Z., Luo, X., Dai, R.-C., Zhou, H., Wu, X.-P., & Liao, E.-Y. (2013) · International Journal of Endocrinology · doi:10.1155/2013/727164 · Cited by 3
“In postmenopausal women, the circulating OPG level affects bone turnover, changes in bone mass, and the prevalence of vertebral fractures [6, 7].”
Background[Neurosurgical treatments for pain].
Pirotte, B. J. M. (2012) · PubMed · Cited by 3
Endocrinology of Bone and Growth Disorders
Farquharson, C., Stephen, L. A., & Wong, S. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00086-4 · Cited by 3
Nunes, C. M. M., Bernardo, D. V., Ferreira, C. L., Gomes, M. F., Marco, A. C. D., Santamaria, M. P., & Jardini, M. A. N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081854 · Cited by 2
“Osteoblasts secrete OPG, a soluble receptor that blocks the RANK/RANKL interaction through its binding to RANKL, thereby preventing osteoclast differentiation and activation [48].”
BackgroundThe Regulation of Bone Metabolism by the Liver
Luo, J., Zhang, Y., Fu, Y., Huang, Y., Zou, Z., & Han, L. (2024) · Nature Cell and Science · doi:10.61474/ncs.2023.00018 · Cited by 1
Llavero-Valero, M., Vaamonde, J., Martínez, S. B., & López‐Frías, M. (2018) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2018.11.023 · Cited by 3
Bone turnover markers and prediction of bone loss in elderly women
Lenora, J. (2009) · Lund University Publications (Lund University) · Cited by 2
The Association of Bone Mineral Density with Cardiovascular Disease
Farhat, G. N. (2006) · D-Scholarship@Pitt (University of Pittsburgh)
Fisiología del hueso y marcadores bioquímicos del recambio óseo
Canelas, A. C., Cenarruzabeitia, N. V., & Corrales, E. P. (2014) · Elsevier eBooks · doi:10.1016/b978-84-9022-503-5.00002-2 · Cited by 2
Ashley, D. T. (2010) · Dublin City University Open Access Institutional Repository (Dublin City University)
Efectos del tabaquismo sobre los niveles plasmáticos de osteoprotegerina en adultos jóvenes sanos
Supervía, A., Enjuanes, A., Ruiz-Gaspà, S., Nogués, X., & Díez‐Pérez, A. (2008) · Revista Española de Enfermedades Metabólicas Óseas · doi:10.1016/s1132-8460(08)72479-6 · Cited by 2
Martín-Bautista, E. (2011) · Institutional Repository of the University of Granada (University of Granada)
New strategies of treatment of postmenopausal osteoporosis
Sobczuk, A., Sobczuk, K., & Pertyński, T. (2011) · Menopause Review/Przegląd Menopauzalny
Mokhber, A., Hall, E., Uzelac, A., Salmena, L., Cheung, A. M., Lubiński, J., Narod, S. A., & Kotsopoulos, J. (2024) · Bone Reports · doi:10.1016/j.bonr.2024.101802 · Cited by 1
Xu, W., Li, J., Zhou, J., & Zhang, G. (2025) · Research Square · doi:10.21203/rs.3.rs-7030982/v1
Metadata
- Authors
- Mezquita-Raya, P., de la Higuera, M., García, D. F., Alonso, G., Ruiz-Requena, M. E., de Dios Luna, J., Escobar-Jiménez, F., & Muñoz-Torres, M.
- Affiliations
- Universidad de Granada (ES)
- University Hospital Zurich (CH)
- Venue
- Osteoporosis International
- Published
- 2005-02-12
- Volume
- 16
- Issue
- 11
- Pages
- 1368-1374
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2146240002
- Cited by
- 98
- References
- 31
- Citations by year
- 2025: 1 · 2024: 3 · 2022: 5 · 2021: 1 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 4 · 2013: 5 · 2012: 6
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- osteoprotegerin, RANKL, postmenopausal osteoporosis, vertebral fractures, bone mineral density, bone turnover markers, osteoclast activity, menopause, serum biomarkers, postmenopausal women
- MeSH terms
- Tartrate-Resistant Acid Phosphatase, Acid Phosphatase, Aged, Alkaline Phosphatase, Carrier Proteins, Estradiol, Female, Femur Neck, Glycoproteins, Humans, Isoenzymes, Lumbar Vertebrae, Membrane Glycoproteins, Middle Aged, Prospective Studies, Biomarkers, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.